Minosil (Minocycline Hydrochloride)

Minocycline, the active ingredient in Minosil, is a tetracycline antibiotic presented as an oral dosage form for systemic use. It is employed to treat bacterial infections such as acne vulgaris, respiratory tract infections, urinary tract infections, and various skin and soft‑tissue infections in adult patients. The formulation complies with European Union quality standards and is approved for these indications across many EU member states.

GNH USA supplies Minosil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Minocycline is a broad‑spectrum tetracycline antibiotic used to treat infections in several organ systems.

Acne vulgaris: reduces inflammatory lesions and bacterial colonisation. Respiratory tract infections: eradicates susceptible pathogens causing sinusitis, bronchitis and pneumonia. Urinary tract infections: eliminates common uropathogens and relieves symptoms. Skin and soft‑tissue infections: treats cellulitis, abscesses and infected wounds caused by susceptible bacteria.

Minocycline may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Diarrhea - Photosensitivity - Dizziness

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Drug‑induced liver injury - Severe vestibular toxicity (vertigo, ataxia) - Anaphylactic reaction

Before prescribing Minosil, consider the following precautions.

Assess renal and hepatic function: adjust dose if impairment is present. Avoid use in children under 8 years: risk of permanent tooth discoloration. Do not combine with isotretinoin: increased risk of intracranial hypertension. Monitor for photosensitivity: advise sun protection measures. Pregnancy and lactation: safety not established; weigh benefits against risks. Store at below 25°C: keep in original packaging, protect from moisture.

Minosil can interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption. - Warfarin: may enhance anticoagulant effect. - Oral contraceptives: may decrease efficacy. - Lithium: increased risk of toxicity.

Moderate Interactions (Monitor Closely): - Cyclosporine: increased nephrotoxicity. - Barbiturates: may reduce minocycline levels. - Phenytoin: may decrease effectiveness. - Rifampin: may induce hepatic enzymes and lower concentrations.